A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

NCT07448831 | Recruiting Phase 2

• 2 other identifiers: NeoSenti2024-517840-68
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 1

Brief Summary

This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively. The study includes adults with high-risk melanoma who do not show any signs of the cancer having spread on scans. Participants receive a single infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy. The goal is to see if this early treatment can reduce or eliminate tiny cancer cells that might already be in the lymph nodes but are too small to detect. After surgery, patients whose melanoma stage normally requires further treatment will continue with standard immunotherapy for one year. Others will move directly into follow-up care. All participants are monitored closely for five years with regular scans, blood tests, and check-ups to watch for any signs of recurrence and to ensure their safety.

Conditions

Melanoma (Skin Cancer)

Outcome Measures

Primary Outcomes (1)

• Antitumor activity of pembrolizumab

  To estimate the antitumor activity of pembrolizumab in high-risk primary cutaneous melanoma population (pT1b to pT4b) without clinical evidence of metastasis (cN0M0) in the neoadjuvant setting.

  A period of 7 weeks

Secondary Outcomes (9)

• Relapse-free survival

  A period of 5 years

• Adverse events

  For up to 3 years from the date of last dose of study treatment or until the death or lost to follow-up

• Health-Related Quality of Life (HRQoL)

  Baseline, 6 months, 16 months.

• Presence of cell-free circulating tumor DNA

  At baseline, each 6 weeks during the adjuvant treatment phase before every treatment cycle, each 4 months during the follow-up phase and/or at relapse.

• Distant-metastasis free survival

  A period of 5 years

Study Arms (1)

High-risk primary cutaneous melanoma

EXPERIMENTAL

pT1b-3a Merlin high-risk and pT3b-4b

Drug: Pembrolizumab

Interventions

Pembrolizumab DRUG

One administration of intravenous pembrolizumab 400 mg.

High-risk primary cutaneous melanoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥ 18 years of age on the day of signing the informed consent.
• Histologically confirmed high risk primary cutaneous pT1b-4b melanoma High risk primary melanoma is defined in this study as the following AJCC8 T-stages:
• pT1b-3a, with a poor prognostic score on the Merlin™ test ("Merlin™ high risk");
• pT3b-4b, irrespective of their Merlin™ test result
• Amendable to sentinel lymph node biopsy.
• No evidence of metastatic dissemination as demonstrated by PET/CT, ultrasound of the draining lymph node basin, and clinical examination.
• No prior exposure to systemic treatment for melanoma (adjuvant or curative).
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2 assessed within 7 days prior to the first dose of study treatment.
• Adequate baseline organ function as defined by local institutional standards.
• Women:
• Female patients must be surgically sterile or be postmenopausal (A postmenopausal state is defined as no menses for 12 months without an alternative medical cause).
• If a female patient is a woman of childbearing potential (WOCBP) they must agree to use highly effective contraception measures during the period of therapy, which should be continued for at least 4 months following the last dose of pembrolizumab as indicated in the SmPC. A list of highly effective contraceptive measures is included in appendix 1 All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment and pregnancy testing should be conducted within 24h prior to the first dose of immune checkpoint inhibitors and thereafter monthly until 4 months following the last dose study treatment.
• Should not be breastfeeding at screening or during study treatment.
• Men with a female partner of childbearing potential must agree to use highly effective contraception from 14 days prior to administration of the first dose of study treatment or have either had a prior vasectomy, throughout the treatment period, and for 16 weeks after the last dose of study treatment.
• Capable of providing documented informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

You may not qualify if:

• Patients with uveal melanoma, mucosal melanoma and melanoma of unknown primary origin.
• Active autoimmune disease requiring systemic treatment.
• Patients with a history of previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 3 years prior to screening and no additional therapy is required or anticipated to be required during the study period.
• Known Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Exception: subjects with laboratory evidence of cleared HBV and HCV infection will be permitted.
• Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures.
• Active infection at the time of screening (e.g. wound infection).
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatment, or excipients.
• History of organ allograft.
• Patients who have previously been exposed to checkpoint inhibitors.
• Prior transplantation of human cells, tissues and organs (e.g. liver transplant) or candidates for any type of transplantation.
• History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
• Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Any contra-indication for evaluation by whole body 18F-FDG-PET/CT or MRI.

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel: lead

Study Sites (1)

UZ Brussel

Jette, Brussels Capital, 1090, Belgium

RECRUITING

MeSH Terms

Conditions

Melanoma

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Bart Neyns, Prof, MD, PhD

  Universitair Ziekenhuis Brussel

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2026
• First Posted: March 4, 2026
• Study Start: April 17, 2025
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): December 1, 2029
• Last Updated: March 9, 2026

Record last verified: 2025-12

Locations

BE (1)